Table 1.
Demographic and clinical characteristics by sleep onset latency group (n=307)
| Total Sample (n=307) | Sleep Onset Latency Group
|
Statistics | ||
|---|---|---|---|---|
| ≤30 minutes (n=237) | >30 minutes (n=70) | |||
|
| ||||
| Demographics | ||||
| Age, years, mean (SD) (range 22 – 77) | 44.9 (8.3) | 44.9 (8.4) | 44.9 (8.3) | F(1,305)=0.00, p=.999 |
| Gender | χ2(2,307)=0.68, p=.713 | |||
| Male | 212 (69%) | 162 (68%) | 50 (71%) | |
| Female | 72 (23%) | 58 (25%) | 14 (20%) | |
| Transgender | 23 (8%) | 17 (7%) | 6 (9%) | |
| Race/ethnicity | χ2(2,307)=4.57, p=.102 | |||
| Caucasian | 129 (42%) | 101 (43%) | 28 (40%) | |
| African-American | 113 (37%) | 92 (39%) | 21 (30%) | |
| Other | 65 (21%) | 44 (18%) | 21 (30%) | |
| Education | χ2(2,307)=0.60, p=.741 | |||
| High school or less | 132 (43%) | 103 (43%) | 29 (41%) | |
| Vocational or some college | 107 (35%) | 80 (34%) | 27 (39%) | |
| College degree | 68 (22%) | 54 (23%) | 14 (20%) | |
| Employment, n (%) | χ2(2,307)=0.81, p=.666 | |||
| Employed/student | 49 (16%) | 40 (17%) | 9 (13%) | |
| Unemployed | 18 (9%) | 23 (10%) | 6 (9%) | |
| Disability | 229 (75%) | 174 (73%) | 55 (78%) | |
| Monthly Income | χ2(2,307)=5.36, p=.021 | |||
| < $1,000 | 211 (69%) | 155 (65%) | 56 (80%) | |
| ≥$1,000 | 96 (31%) | 82 (35%) | 14 (20%) | |
|
| ||||
| Clinical Characteristics | ||||
| CD4+ T-cell count (cells/mm3) | n=293a | n=230a | n=63a | χ2(2,293)=0.01, p=.925 |
| <200 | 50 (17%) | 39 (17%) | 11 (17%) | |
| ≥200 | 243 (83%) | 191 (83%) | 52 (83%) | |
| Viral Load (log10 copies/mL) | n=287a | n=226a | n=61a | χ2(2,287)=4.12, p=.042 |
| Undetectable | 146 (51%) | 122 (54%) | 24 (39%) | |
| Detectable | 141 (49%) | 104 (46%) | 37 (61%) | |
| Years since HIV diagnosis | F(1,305)=0.00, p=.973 | |||
| Mean (SD), range 0.2 - 26 | 12.1 (7.0) | 12.1 (7.0) | 12.1 (7.0) | |
| Anti-retroviral therapy | χ2(2,307)=0.12, p=.726 | |||
| Not on treatment | 87 (28%) | 66 (28%) | 21 (30%) | |
| On treatment | 220 (72%) | 171 (72%) | 49 (70%) | |
| AIDS Diagnosis | χ2(2,307)=0.08, p=.772 | |||
| No | 145 (47%) | 113 (48%) | 32 (46%) | |
| Yes | 162 (53%) | 124 (52%) | 38 (54%) | |
| Body mass index, mean (SD) | ||||
| Male | 26.1 (4.8) | 25.7 (4.2) | 27.2 (6.5) | F(1,210)=3.54, p=.061 |
| Female | 28.9 (6.4) | 29.5 (6.5) | 26.8 (5.5) | F(1,70)=1.98, p=.164 |
| Transgender | 28.9 (6.7) | 29.1 (6.7) | 28.6 (7.7) | F(1,21)=0.02, p=.895 |
Note: SD = standard deviation; Bolded variables are associated (p < 0.10) with sleep group and were evaluated as potential covariates in adjusted regression models. Use of sleep medication, anxiolytics, antidepressants, or opiates was not associated with sleep group.
a
Sample sizes were lower due to missing data from medical records